Archived Press Releases

July 26, 2011

Diffusion Pharmaceuticals Receives FDA Orphan Status for TSC, a First-in-Class Drug for the Treatment of Primary Brain Cancer

Charlottesville, VA – July 26, 2011 – Diffusion Pharmaceuticals LLC announced today that trans sodium crocetinate (TSC), the company’s lead drug candidate, has been granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary brain cancer, also known as glioblastoma multiforme or GBM.  GBM is one of [...]

May 1, 2011

Diffusion Pharmaceuticals Closes on $2.2 Million Financing; Plans Clinical Trial In Primary Brain Cancer

CHARLOTTESVILLE, VA – May 1, 2011 – Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat life-threatening unmet medical conditions, today announced that it closed on an additional $2.2 million in private financing during the first quarter of 2011. The financing consisted of convertible notes issued to existing investors. Proceeds will support [...]

November 15, 2010

Diffusion Pharmaceuticals Achieves Positive Results in Phase I/II Clinical Trial of Trans Sodium Crocetinate in Peripheral Artery Disease; Drug Offers Promise for Range of Serious Hypoxia-Related Medical Conditions

“Given the dearth of successful clinical research options in PAD, these study results are exciting,” said study presenter William Hiatt, MD, professor of cardiovascular research in the Department of Medicine, University of Colorado School of Medicine; President of CPC Clinical Research and chairman of the American Heart Association’s Peripheral Vascular Disease Council.

November 9, 2010

Results of Phase I/II Clinical Trial of TSC in Patients with Peripheral Artery Disease (PAD) to be Presented at American Heart Association Scientific Sessions November 15, 2010

November 4, 2010

Diffusion Pharmaceuticals One of 45 Virginia Companies to Receive Federal Grant

“This non-dilutive award will advance our clinical program and aid us in our mission to introduce approved novel and effective therapies as quickly as possible, providing new hope for patients with PAD, cancer and other conditions related to hypoxia,” said David G. Kalergis, CEO, Diffusion Pharmaceuticals.”